Viennese acib and BOKU researchers are developing a sterile 3D printing process that can be used to produce laboratory equipment from environmentally friendly and biodegradable plastic. This could avoid several million tons of single-use plastic waste and reduce resource, energy
Researchers have found a way to make the industrial production of pharmaceuticals, as well as flavorings and biopolymers, more environmentally friendly: Unlike chemical processes that use toxic heavy metals, the new biocatalytic synthesis pathway uses natural enzymes as reaction accelerators.
Carbon serves as the building block of life, as well as the goods and products we use every day. We consume fossil fuels and use carbon to make plastic and a variety of other products. Life as we know it
Viennese researchers from the Austrian Centre of Industrial Biotechnology (acib) and BOKU Vienna found a way to use the harmful greenhouse gas CO2 as a raw material for the production of industrial products such as bioplastics, absorbents or important chemicals
The MOOC “The new plastics economy: circular business models and sustainability”, realized within the Horizon 2020 BIO-PLASTICS EUROPE project
One of the greatest difficulties in combating viral infectious diseases is the excellent adaptability of viruses. Especially with of SARS-CoV-2 new variants are quickly and constantly forming, bringing different properties with them. That’s why it’s important that in the future
Sustainability and use of renewable resources represent an important part of any production process with regard to circular economy and for the sake of our planet. With all the biomass available, utilization thereof offers a variety of applications. The European
Co-Authors: Martin Walpot & Doris Ribitsch An enzyme called tyrosinase, which is responsible for triggering a protective mechanism in plants and turning apples brown, even possesses further, previously unknown properties: For the first time, acib researchers have used the proteolytic
The pharmaceutical industry has had to resort to rather inefficient, environmentally harmful chemical synthesis routes for the production of the active ingredient levetiracetam, a drug which is used to treat epilepsy. A consortium led by acib has now developed a